<DOC>
	<DOCNO>NCT00699790</DOCNO>
	<brief_summary>The purpose study determine whether CCR2 antagonist ( BMS-741672 ) improve glucose homeostasis drug-naive type 2 diabetic patient</brief_summary>
	<brief_title>Proof Confidence Study CCR2 Antagonist ( BMS-741672 ) Insulin Resistance</brief_title>
	<detailed_description />
	<criteria>Drugnaive Type 2 diabetic screen HbA1c ≥ 7.5 % ≤ 10 % Screening FPG ≥ 140 mg/dL ≤ 220 mg/dL BMI ≤ 40 kg/m2 Active tuberculosis Symptoms poorly control diabetes History diabetic ketoacidosis Significant cardiovascular history gastrointestinal disorder History unstable rapidly progress renal disease Active liver disease and/or significant abnormal liver function Abnormal chest xray screen indicative tuberculosis infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>NOS</keyword>
</DOC>